- Trials with a EudraCT protocol (29)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
29 result(s) found for: Assisted Living Facility.
Displaying page 1 of 2.
EudraCT Number: 2021-002225-18 | Sponsor Protocol Number: 217131 | Start Date*: 2021-09-22 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase 3, randomized, double-blind, multi-country study to evaluate consistency, safety, and reactogenicity of 3 lots of RSVPreF3 OA investigational vaccine administrated as a single dose in adult... | ||
Medical condition: Respiratory Syncytial Virus Infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-005161-18 | Sponsor Protocol Number: DEB-ZTSR-201 | Start Date*: 2007-01-17 | |||||||||||
Sponsor Name:Debiopharm | |||||||||||||
Full Title: A randomised, double-blind, double-dummy, oral donepezil controlled study on the safety and efficacy of repeated monthly subcutaneaous injections of a sustained-release implant of ZT-1 in patients ... | |||||||||||||
Medical condition: moderate Alzheimer disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014424-29 | Sponsor Protocol Number: H6L-MC-LFBF (b) | Start Date*: 2010-02-05 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: Open-Label Extension for Alzheimer’s Disease Patients Who Complete One of Two Semagacestat Phase 3 Double-Blind Studies (H6L-MC-LFAN or H6L-MC-LFBC) | ||
Medical condition: Alzheimer's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) DE (Completed) ES (Prematurely Ended) BE (Completed) IT (Completed) FR (Completed) SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003306-40 | Sponsor Protocol Number: E2006-G000-202 | Start Date*: 2018-02-27 |
Sponsor Name:Eisai Ltd. | ||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study with Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects with Irregular Sleep-Wake Rhy... | ||
Medical condition: Irregular Sleep-Wake Rhythm Disorder in Subjects with Mild to Moderate Alzheimer’s Disease Dementia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000504-41 | Sponsor Protocol Number: 331-12-283 | Start Date*: 2013-12-10 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: Country-specific protocol amendment for Germany entitled: A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2... | |||||||||||||
Medical condition: Agitation Associated with Dementia of the Alzheimer’s Type | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000835-84 | Sponsor Protocol Number: 30982081-CAP-3001 | Start Date*: 2006-10-10 | |||||||||||
Sponsor Name:Jansen-Cilag International N.V. | |||||||||||||
Full Title: Randomized, Double-Blind, Multicenter Study of Ceftobiprole Medocaril Versus Ceftriaxone with/without Linezolid in Treatment of Subjects Hospitalized With Community-Acquired Pneumonia | |||||||||||||
Medical condition: Hospitalized community acquired pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LT (Completed) HU (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000623-21 | Sponsor Protocol Number: 218350 | Start Date*: 2022-09-21 |
Sponsor Name:GlaxoSmithKline, S.A. | ||
Full Title: A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety and reactogenicity of an RSVPreF3 OA investigational vaccine when co-administered with F... | ||
Medical condition: Respiratory syncytial virus infection | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005755-20 | Sponsor Protocol Number: ALZ-801-AD301 | Start Date*: 2021-06-21 | |||||||||||
Sponsor Name:Alzheon, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease and APOE4/4 Genotype | |||||||||||||
Medical condition: Early Alzheimer’s Disease (AD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) NL (Ongoing) ES (Ongoing) IS (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003740-23 | Sponsor Protocol Number: AB13004 | Start Date*: 2015-02-04 | |||||||||||
Sponsor Name:AB Science | |||||||||||||
Full Title: A prospective, multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 2b/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patien... | |||||||||||||
Medical condition: Progressive Supranuclear Palsy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004719-28 | Sponsor Protocol Number: D8850C00003 | Start Date*: 2020-11-20 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004918-14 | Sponsor Protocol Number: A2501056 | Start Date*: 2008-05-06 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York,NY 10017 | |||||||||||||
Full Title: A 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE IMPACT OF DONEPEZIL HYDROCHLORIDE (ARICEPT®) ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN PATIENTS WITH SEVERE ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: SEVERE ALZHEIMER’S DISEASE | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019159-23 | Sponsor Protocol Number: AL-108-231 | Start Date*: 2010-11-08 | |||||||||||
Sponsor Name:Allon Therapeutics Inc | |||||||||||||
Full Title: A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. | |||||||||||||
Medical condition: Progressive Supranuclear Palsy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000429-38 | Sponsor Protocol Number: PLX108-15 | Start Date*: 2016-08-31 | ||||||||||||||||
Sponsor Name:Plexxikon Inc. | ||||||||||||||||||
Full Title: A Phase 2a Study of the Safety, Tolerability, and Pharmacodynamic Effects of Pexidartinib in Subjects with Mild to Moderate Alzheimer’s Disease | ||||||||||||||||||
Medical condition: Alzheimer's Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000503-17 | Sponsor Protocol Number: 331-12-284 | Start Date*: 2015-01-29 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Flexible Dosing of Brexpiprazole (OPC-34712) in the Treatme... | |||||||||||||
Medical condition: Agitation Associated with Dementia of the Alzheimer’s Type | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FI (Prematurely Ended) SI (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000095-25 | Sponsor Protocol Number: DIM14 | Start Date*: 2008-12-22 | |||||||||||
Sponsor Name:Medivation, Inc. | |||||||||||||
Full Title: CONNECTION: A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients with Mild-to-Moderate Alzheimer’s Disease | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) SE (Completed) DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003302-27 | Sponsor Protocol Number: ANAVEX2-73-AD-004 | Start Date*: 2020-01-22 | |||||||||||
Sponsor Name:Anavex Germany GmbH | |||||||||||||
Full Title: A Phase 2b/3, Double-Blind, Randomised, Placebo-Controlled 48 week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer’s Disease (AD). | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001128-78 | Sponsor Protocol Number: ACP-103-033 | Start Date*: 2017-03-21 | |||||||||||
Sponsor Name:ACADIA Pharmaceuticals Inc. | |||||||||||||
Full Title: A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer’s Disease | |||||||||||||
Medical condition: Agitation and Aggression in Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004325-80 | Sponsor Protocol Number: ANAVEX2-73-AD-EP-004 | Start Date*: 2022-01-10 | |||||||||||
Sponsor Name:Anavex Germany GmbH | |||||||||||||
Full Title: Open Label Extension Study for Patients with Early Alzheimer’s Disease (AD) Enrolled in Study ANAVEX2-73-AD-004 | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000213-11 | Sponsor Protocol Number: CENA713D2340 | Start Date*: 2007-09-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm2 Patch in Patients with Alzheimer’s Disease... | |||||||||||||
Medical condition: Alzheimer’s disease dementia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000986-17 | Sponsor Protocol Number: ALZ-801-201ADBM | Start Date*: 2020-09-11 |
Sponsor Name:Alzheon Inc. | ||
Full Title: A Phase 2, Single Arm, Study of the Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer’s Disease Who Are Carriers of the ε4 Variant of the Apolipoprotein E Gene (APOE4/4 or APOE3/4) | ||
Medical condition: Subjects with a clinical diagnosis of Alzheimer's disease who are APOE 4 carriers (APOE4/4, APOE3/4) and at the Early stage of disease, ages 50-80 years | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Ongoing) NL (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.